VAP Diagnosis Conundrum
Two competing timelines have been developed for diagnosing VAP. The first is the CDC's National Healthcare Safety Network surveillance classification that defines VAP as pneumonia that occurs in a patient who was intubated and ventilated at the time of, or within 48 hrs, "before" the onset of the pneumonia (4) . The second is the more clinically oriented American Thoracic Society and the Infectious Disease Society of America pneumonia guidelines that define VAP as pneumonia that arises Ͼ48 -72 hrs "after" intubation (2) . Regardless of these different approaches to VAP timing, the VAP diagnostic criteria require the presence of a new or progressive and persistent radiographic opacity, a change in pulmonary secretions or symptoms, or evidence of impaired gas exchange and systemic signs of infection (4) . Microbiological evidence of lower respiratory tract infection is optional.
The radiographic criteria used to diagnose VAP rely on subjective interpretations of lung parenchymal changes that may be subtle, transient, and difficult to discern in an ICU patient. These opacities often do not follow typical anatomic distribution and are often obscured by pleural effusions, atelectasis, pulmonary edema, or postoperative changes. Daily chest radiograph comparisons may also be confusing if radiologic techniques or patient positioning are inconsistent (5, 6) . In fact, in our opinion, the sole reliance on basic chest radiography in the current CDC algorithm fails to appreciate the expanded role of computed tomography imaging in the diagnosis of pulmonary pathologies among ICU patients (7) .
Thus, although the overall CDC approach may have been devised to simplify and standardize the diagnosis of VAP, in reality, this has not occurred. Even with careful application of the VAP algorithm, studies have shown high interobserver variability (8), misdiagnosis and overdiagnosis (9), poor sensitivity (69%), and poor specificity (75%), especially when compared with postmortem lung specimens from ventilated patients with biopsyproven pneumonia (10) . VAP may also have been confused in the past with ventilator-associated tracheobronchitis (11, 12) . Variable VAP surveillance definitions and diagnostic thresholds may result from the multiplicity of microbiologic collection methods, use of serum biomarkers of lung injury (10), modified versions of the CDC algorithm, and computerized diagnostic VAP programs (9, 13) . Even the authors of the Michigan Keystone ICU VAP prevention project, which demonstrated a dramatic 71% reduction in VAP rates, acknowledged that the lack of a uniform surveillance definition of VAP was a significant limitation of their study (14) .
VAP Bundle
The ventilator bundle concept originated in 2005 from the Institute for Healthcare Improvement's (IHI) 100,000 Lives Campaign (15) . The IHI-defined bundle initially had four purportedly evidenced-based elements (head of bed elevation, daily sedation vacation, stress ulcer prophylaxis, and deep venous thrombosis prophylaxis) that would improve clinical outcomes in patients on mechanical ventilation if "all" the bundle elements were concomitantly used. In May 2010, a fifth component (oral decontamination with chlorhexidine) was added (16) .
Resar and colleagues were the first group to demonstrate that ICUs which achieved Ͼ95% compliance with the VAP bundle had an average VAP reduction rate of 44.5% (17) . However, the authors ac-knowledged that the reduction in VAP rates may have resulted primarily from the involvement of multidisciplinary teams, daily goal-setting, and increased focus of care on the ventilated patient rather than adherence to the bundle elements. This is because not all the elements of the bundle were even intended to reduce VAP. Other studies have noted modest and unsustained improvements in VAP rates using the bundle (17, 18) . Nevertheless, as VAP rates were reduced, the ventilator bundle was transformed from being an "outcomes improvement" tool to a "VAP prevention" strategy. Subsequently, hospital quality improvement groups nationwide adopted the VAP bundle as essential to reducing VAP rates rather than serving as a motivator to improve ICU care of the ventilated patient (19) . Unfortunately, clinicians were encouraged to implement the VAP bundle and demonstrate compliance, whether they agreed with the bundle concept or its clinical applicability or not.
Methodologic inconsistencies have been found in studies that support several of the IHI bundle elements (20) . These include variabilities in VAP diagnostic strategies, the application and compliance with bundle elements, and the assignment of personnel to diagnose VAP before and after bundle implementation. The IHI has also been overly expansive in applying the bundle beyond the evidence. For example, oral decontamination with chlorhexidine is recommended by the IHI for all ventilated patients. However, the supporting studies show benefits only in two select ICU populations, surgical and trauma patients (21) . Additionally, IHI bundle recommendations may have either no effect on VAP (deep venous thrombosis prophylaxis) or may be nearly impossible to achieve even in research settings (head of bed elevation 30 -45°) (22) . Furthermore, selected bundle elements have been associated with harmful repercussions. The routine use of stress ulcer prophylaxis may potentiate hospital-acquired pneumonia in ventilated patients (23) , particularly with the use of histamine-2-receptor antagonists among those receiving enteral nutrition (24) . The use of stress ulcer prophylaxis has also been associated with nosocomial and recurrent Clostridium difficile infection (25, 26) . Even elevation of the head of the bed to 45°may increase the risk of thromboembolism or hemodynamic instability (27) .
Benefits of VAP Bundle
Concomitant ICU benefits would be expected with the reductions in VAP rates that have been reported (17, 18, 21, 28) . Such benefits might include fewer days on mechanical ventilation and in the ICU, as well as lower antibiotic use, ICU costs, and mortality. To our knowledge, beyond some individually inferred cost benefits (20, 29 -31) , there are few studies that incontrovertibly demonstrate a return on the VAP prevention and reporting investment (21, 32).
VAP-Industrial Complex
The "VAP-industrial complex" is marketing new products purported to decrease VAP rates. The phrase "VAP prevention" is now attached to any item that can literally or figuratively be associated with the airways or lungs. These range from hospital beds having continuous lateral rotation capability to inline suction catheters, humidifiers, ventilator circuits, and a variety of "designer" endotracheal tubes. Although many of the new endotracheal tubes have been studied, only those with subglottic secretion draining are recommended in VAP prevention guidelines (33), an approach not incorporated into the VAP bundle. Regardless of the data, hospitals may feel pressured by relentless advertising and a desire to "do the right thing" and purchase such devices without the usual due diligence appropriate to evaluate such items (34) .
Reporting of Quality Metrics
Intensivists, infectious disease specialists, infection preventionists, and quality improvement administrators may view the VAP bundle, VAP surveillance and diagnostic strategies, and the process of gathering and reporting such data through their own differing clinical and bureaucratic perspectives. Nevertheless, there is a fascination with patient care statistics and a mandate to report them in an attempt to measure quality and demonstrate safety. Although quality metrics data may satisfy the needs of ICUs, hospitals, regulatory agencies, and the public, these data may also be misleading. The present methods of quantifying and expressing bundle compliance (18) and VAP rates (35) are heavily encumbered with bias and subjectivity. Within institutions, it is necessary, in our opinion, to adjudicate the differences between surveillance and clinical VAP rates, especially the timing of VAP onset and the assignment of location for the VAP event (e.g., postanesthesia care unit, ICU or stepdown unit) (36) . Between institutions, comparability of VAP data may also be compromised by a diversity of case mix, bundle elements, and surveillance protocols (37) . Additionally, hospitals may approach data collection and reporting differently. Some report compliance with the VAP bundle process without addressing VAP rates hoping that this will be sufficient for quality improvement mandates (38) . Others will quantify and report both bundle and surveillance data.
We believe that data gathering for VAP compliance and reporting would be greatly advanced if the CDC, IHI, and other quality improvement organizations would develop universally applicable automated systems to monitor compliance and surveillance and eliminate all the subjective elements. The CDC, with their collaborators, has already set up such software for reporting outpatient-based notifiable diseases (39) . Currently, hospitals are left to manually enter VAP data into an online National Healthcare Safety Network pneumonia reporting form and have only begun to trial their own proprietary VAP surveillance and compliance systems.
The Quest for Zero VAP
Although the idea of achieving "zero VAP" may be optimal, this objective must be counterbalanced by realism and not punishment. Pneumonia will always be a part of the ICU environment, whether a patient is on mechanical ventilation or not (40) . Even high-end, multifaceted programs extensively targeting VAP only show a partial reduction in VAP rates (17, 18 ). An editorialist recently suggested "that it might be possible to achieve an apparent VAP rate of zero by maximally exploiting the subjectivity and inconsistencies of VAP definitions" (41) .
The VAP Bureaucracy
The Joint Commission's patient safety advisory group recently concluded that VAP will not be adopted as a National Patient Safety Goal in the near future because VAP cannot be consistently de-fined, identified or measured (42) . The CDC has also recognized the subjectivity and complexity of their VAP surveillance definition and is currently working on a modified diagnostic algorithm (S.S. Magill, personal communication, 2011). Nevertheless, ICUs are still mandated to comply with hospital and state-based VAP bundle and surveillance programs even as VAP lingers in diagnostic and bureaucratic flux.
CONCLUSION
We are left with several puzzling questions (Fig. 1) . Is it possible to have a standardized definition of VAP? Do higher rates of bundle compliance actually lead to decreased VAP? Does VAP surveillance improve preventive practices or merely exist to provide target numbers for reporting purposes? Does a VAP rate above zero suggest substandard care? And where are the VAP reduction costeffectiveness studies that analyze all costs involved in implementing a comprehensive VAP prevention program? The inability of The Joint Commission and the CDC to resolve the VAP diagnostic conundrum, in combination with the issues we raise, leads us to suggest that the current agenda of mandatory VAP surveillance and reporting be abandoned and the VAP bundle deconstructed. As the social ecologist Peter Drucker said, "There is nothing so useless as doing efficiently that which should not be done at all" (43) .
